This review explores the maternal gut microbiome’s role in shaping neonatal neurodevelopmental outcomes following perinatal asphyxia (PA), a leading cause of infant mortality and disability with limited therapeutic options beyond hypothermia. We synthesized current evidence on microbiome-mediated neuroprotective mechanisms against hypoxic-ischemic brain injury. The maternal microbiome influences fetal development through bioactive metabolites (short-chain fatty acids, indole derivatives) that cross the placental barrier, bacterial antigen regulation, and infant microbiome colonization. These pathways activate multiple protective mechanisms: anti-inflammatory signaling via NF-κB suppression and regulatory T cell expansion; antioxidant defenses through Nrf2 activation; neural repair via BDNF upregulation and neurogenesis; and oxytocin system modulation. Animal models demonstrate that maternal dysbiosis from high-fat diet or antibiotics exacerbates PA-induced brain damage, increasing inflammatory markers and hippocampal injury. Conversely, probiotic supplementation, dietary fiber, and specific interventions (omega-3, resveratrol) reduce neuroinflammation and oxidative injury. Human studies link maternal dysbiosis-associated conditions (obesity, gestational diabetes) with adverse pregnancy outcomes, though direct clinical evidence for PA severity remains limited. Understanding the maternal microbiome-fetal brain axis opens therapeutic avenues, including prenatal probiotics, dietary modifications, and targeted metabolite supplementation to prevent or mitigate PA-related neurological sequelae, potentially complementing existing neuroprotective strategies.
25 March 2026 in Medicina Moderna - Modern Medicine
Dystonia is a rare movement disorder, defined by intermittent or sustained involuntary movements and/or postures. The term can refer both to a clinical syndrome and to a group of primary movement disorders in which dystonia represents the predominant manifestation. Adult-onset isolated focal dystonia is the most common form. The aim of this narrative review is to present the current understanding of adult-onset isolated focal dystonia, focusing on its recently revised classification, pathogenesis, and therapeutic approaches. The updated classification system emphasize a two-axis framework integrating clinical features and aetiology, therefore facilitating improved phenotypic characterization and differential diagnosis. The underlying pathophysiological mechanisms of isolated focal dystonia remain incompletely understood, both genetic and environmental factors playing a role. Contemporary models conceptualise dystonia as a network disorder involving the striato–thalamo–cortical and cerebellar circuitry, with evidence supporting impaired inhibitory control, abnormal sensorimotor integration, and maladaptive neuroplasticity. The treatment remains largely symptomatic, with botulinum toxin representing first-line therapy, although its efficacy may be limited in some cases.